Julio Rosenstock

66.3k total citations · 32 hit papers
414 papers, 36.4k citations indexed

About

Julio Rosenstock is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Julio Rosenstock has authored 414 papers receiving a total of 36.4k indexed citations (citations by other indexed papers that have themselves been cited), including 371 papers in Endocrinology, Diabetes and Metabolism, 146 papers in Molecular Biology and 134 papers in Surgery. Recurrent topics in Julio Rosenstock's work include Diabetes Treatment and Management (323 papers), Diabetes Management and Research (232 papers) and Metabolism, Diabetes, and Cancer (139 papers). Julio Rosenstock is often cited by papers focused on Diabetes Treatment and Management (323 papers), Diabetes Management and Research (232 papers) and Metabolism, Diabetes, and Cancer (139 papers). Julio Rosenstock collaborates with scholars based in United States, Germany and Canada. Julio Rosenstock's co-authors include Matthew C. Riddle, Melanie J. Davies, John B. Buse, Ildiko Lingvay, Thomas A. Wadden, John Gerich, Juan P. Frías, Sean Wharton, Barbara McGowan and Robert F. Kushner and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Julio Rosenstock

392 papers receiving 34.8k citations

Hit Papers

Once-Weekly Semag... 2003 2026 2010 2018 2021 2009 2003 2021 2005 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Once-Weekly Semaglutide in Adults with Overweight or Obesity
    2021 2.5k citations John Wilding, Rachel L. Batterham et al. New England Journal of Medicine profile →
  2. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
    2009 1.2k citations John B. Buse, Julio Rosenstock et al. The Lancet profile →
  3. The Treat-to-Target Trial
    2003 1.2k citations Julio Rosenstock et al. Diabetes Care profile →
  4. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
    2021 1.1k citations Juan P. Frías, Melanie J. Davies et al. New England Journal of Medicine profile →
  5. Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea
    2005 959 citations Julio Rosenstock et al. Diabetes Care profile →
  6. Effect of Rimonabant, a Cannabinoid-1 Receptor Blocker, on Weight and Cardiometabolic Risk Factors in Overweight or Obese Patients
    2006 948 citations Julio Rosenstock et al. profile →
  7. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials
    2021 921 citations Naveed Sattar, Kelley R. Branch et al. profile →
  8. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
    2021 806 citations Melanie J. Davies, Julio Rosenstock et al. The Lancet profile →
  9. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk
    2018 756 citations Julio Rosenstock, Vlado Perkovic et al. profile →
  10. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
    2021 648 citations Julio Rosenstock, Juan P. Frías et al. The Lancet profile →
  11. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial
    2004 567 citations Julio Rosenstock, Uma Sharma et al. profile →
  12. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
    2022 515 citations John Wilding, Rachel L. Batterham et al. Diabetes Obesity and Metabolism profile →
  13. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
    2021 503 citations Hertzel C. Gerstein, Naveed Sattar et al. New England Journal of Medicine profile →
  14. Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea
    2013 404 citations Guntram Schernthaner, Julio Rosenstock et al. Diabetes Care profile →
  15. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes
    2019 394 citations Julio Rosenstock, Steven E. Kahn et al. profile →
  16. Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes
    2012 364 citations Julio Rosenstock et al. Diabetes Care profile →
  17. Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes
    2017 347 citations Melanie J. Davies, Julio Rosenstock et al. profile →
  18. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea
    2019 302 citations Julio Rosenstock, Melanie J. Davies et al. profile →
  19. Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes
    2014 292 citations Julio Rosenstock et al. Diabetes Care profile →
  20. Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From aDiabetes CareEditors’ Expert Forum
    2017 275 citations William T. Cefalu, Hertzel C. Gerstein et al. Diabetes Care profile →
  21. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
    2023 259 citations Sean Wharton, Julio Rosenstock et al. New England Journal of Medicine profile →
  22. Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials
    2018 244 citations Julio Rosenstock, David Z.I. Cherney et al. Diabetes Care profile →
  23. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
    2023 232 citations Julio Rosenstock, Juan P. Frías et al. The Lancet profile →
  24. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
    2023 231 citations Julio Rosenstock, W. Timothy Garvey et al. The Lancet profile →
  25. Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616
    2023 109 citations Julio Rosenstock et al. profile →
  26. Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin
    2023 91 citations Julio Rosenstock, Stephen C. Bain et al. New England Journal of Medicine profile →
  27. Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial
    2023 88 citations Julio Rosenstock et al. profile →
  28. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial
    2023 86 citations Julio Rosenstock et al. The Lancet profile →
  29. Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes
    2023 82 citations Julio Rosenstock, Juan P. Frías et al. profile →
  30. Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes
    2025 44 citations Rajiv Agarwal, Jennifer B. Green et al. New England Journal of Medicine profile →
  31. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes
    2025 21 citations Julio Rosenstock, Yanyun Chen et al. New England Journal of Medicine profile →
  32. Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
    2025 19 citations Melanie J. Davies, Ildiko Lingvay et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Julio Rosenstock United States 94 29.8k 11.6k 11.4k 7.7k 5.0k 414 36.4k
Michael A. Nauck Germany 97 39.1k 1.3× 17.8k 1.5× 17.3k 1.5× 7.1k 0.9× 5.9k 1.2× 382 47.2k
Sten Madsbad Denmark 87 17.0k 0.6× 11.7k 1.0× 7.1k 0.6× 2.9k 0.4× 7.1k 1.4× 545 27.6k
Tina Vilsbøll Denmark 73 14.9k 0.5× 8.1k 0.7× 7.0k 0.6× 2.6k 0.3× 3.4k 0.7× 455 20.3k
Silvio E. Inzucchi United States 85 32.3k 1.1× 12.0k 1.0× 13.6k 1.2× 3.3k 0.4× 4.7k 0.9× 416 44.4k
Filip K. Knop Denmark 74 12.4k 0.4× 7.7k 0.7× 6.0k 0.5× 2.4k 0.3× 3.7k 0.7× 552 18.8k
Darren K. McGuire United States 85 25.8k 0.9× 10.7k 0.9× 9.8k 0.9× 3.0k 0.4× 3.7k 0.7× 461 40.0k
Robert R. Henry United States 83 12.8k 0.4× 7.0k 0.6× 11.0k 1.0× 2.2k 0.3× 7.1k 1.4× 292 27.8k
André Scheen Belgium 67 10.7k 0.4× 4.5k 0.4× 5.3k 0.5× 3.6k 0.5× 3.9k 0.8× 759 19.9k
Juris J. Meier Germany 69 12.0k 0.4× 8.1k 0.7× 5.9k 0.5× 2.3k 0.3× 2.5k 0.5× 208 17.2k
Ralph A. DeFronzo United States 88 19.4k 0.7× 8.1k 0.7× 13.5k 1.2× 2.6k 0.3× 11.9k 2.4× 284 38.6k

Countries citing papers authored by Julio Rosenstock

Since Specialization
Citations

This map shows the geographic impact of Julio Rosenstock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julio Rosenstock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julio Rosenstock more than expected).

Fields of papers citing papers by Julio Rosenstock

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julio Rosenstock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julio Rosenstock. The network helps show where Julio Rosenstock may publish in the future.

Co-authorship network of co-authors of Julio Rosenstock

This figure shows the co-authorship network connecting the top 25 collaborators of Julio Rosenstock. A scholar is included among the top collaborators of Julio Rosenstock based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julio Rosenstock. Julio Rosenstock is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Agarwal, Rajiv, Jennifer B. Green, Hiddo J.L. Heerspink, et al.. (2025). Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes. New England Journal of Medicine. 393(6). 533–543. 44 indexed citations breakdown →
2.
Tang, W.H. Wilson, Yuxi Liu, Javed Butler, et al.. (2025). Impaired Exercise Capacity in High-Risk Diabetic Cardiomyopathy: The ARISE-HF Cardiopulmonary Exercise Testing Subanalysis. Circulation Heart Failure. 18(3). e012200–e012200. 1 indexed citations
3.
Marwick, Thomas H., Yuxi Liu, Stefano Del Prato, et al.. (2025). Echocardiographic phenotypes of diabetic myocardial disorder: evolution over 15 months follow-up in the ARISE-HF trial. Cardiovascular Diabetology. 24(1). 16–16. 2 indexed citations
4.
Bergman, Brandon K., Julio Rosenstock, W. Timothy Garvey, et al.. (2025). Time spent in glycaemic control with sustained body weight reduction with tirzepatide: A post hoc analysis of the SURPASS clinical trial programme. Diabetes Obesity and Metabolism. 27(6). 3223–3232.
5.
Januzzi, James L., Stefano Del Prato, Julio Rosenstock, et al.. (2024). Characterizing diabetic cardiomyopathy: baseline results from the ARISE-HF trial. Cardiovascular Diabetology. 23(1). 49–49. 12 indexed citations
6.
Prato, Stefano Del, Chinthanie Ramasundarahettige, Kelley R. Branch, et al.. (2024). Impact of baseline FIB-4 score on efpeglenatide benefits on cardiovascular outcomes in people with type 2 diabetes: a participant-level exploratory analysis of the AMPLITUDE-O trial. Cardiovascular Diabetology. 23(1). 352–352.
7.
Gouda, Pishoy, Yuxi Liu, Stefano Del Prato, et al.. (2024). Relationship between NT-proBNP, echocardiographic abnormalities and functional status in patients with subclinical siabetic cardiomyopathy. Cardiovascular Diabetology. 23(1). 281–281.
8.
9.
Heerspink, Hiddo J.L., Melanie J. Davies, Dror Dicker, et al.. (2023). Effects of Semaglutide on Albuminuria and Kidney Function in People With Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis From the STEP 1, 2, and 3 Trials. Diabetes Care. 46(4). 801–810. 63 indexed citations
10.
Home, Philip, et al.. (2022). Findings for iGlarLixi versus BIAsp 30 confirmed in groups of people with type 2 diabetes with different biomedical characteristics. Diabetes Obesity and Metabolism. 25(3). 656–663. 5 indexed citations
11.
Lam, Carolyn S.P., Chinthanie Ramasundarahettige, Kelley R. Branch, et al.. (2021). Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial. Circulation. 145(8). 565–574. 82 indexed citations
12.
Wilding, John, Rachel L. Batterham, Salvatore Calanna, et al.. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 384(11). 989–1002. 2476 indexed citations breakdown →
13.
McGuire, Darren K., John H. Alexander, Odd Erik Johansen, et al.. (2019). Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. Circulation. 139(3). 351–361. 112 indexed citations
14.
Hollander, Priscilla, Raymond L. H. Lam, Gregory T. Golm, et al.. (2018). Efficacy and safety of MK‐1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open‐label clinical trial. Diabetes Obesity and Metabolism. 20(9). 2229–2237. 10 indexed citations
15.
Rosenstock, Julio, Louis Chaykin, Joerg Luedemann, et al.. (2018). Consistent HbA1c and Body Weight Reduction with Semaglutide Independent of Diabetes Duration—SUSTAIN 1-5 and 7 Patient-Level Meta-analysis. Diabetes. 67(Supplement_1). 1 indexed citations
16.
17.
18.
19.
Rosenstock, Julio, et al.. (2008). Efficacy and Safety of Technosphere Inhaled Insulin Compared With Technosphere Powder Placebo in Insulin-Naive Type 2 Diabetes Suboptimally Controlled With Oral Agents.. Diabetes Care. 23 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael A. Nauck Breakdown of academic impact, for papers by Sten Madsbad Breakdown of academic impact, for papers by Tina Vilsbøll Breakdown of academic impact, for papers by Silvio E. Inzucchi Breakdown of academic impact, for papers by Filip K. Knop Breakdown of academic impact, for papers by Darren K. McGuire Breakdown of academic impact, for papers by Robert R. Henry Breakdown of academic impact, for papers by André Scheen Breakdown of academic impact, for papers by Juris J. Meier Breakdown of academic impact, for papers by Ralph A. DeFronzo
Rankless by CCL
2026